Early trial halted: testing a powerful combo for tough head & neck cancers
NCT ID NCT02819752
Summary
This early-stage study aimed to find a safe dose for combining a new immunotherapy drug (pembrolizumab) with standard chemotherapy and radiation for patients with advanced head and neck cancer. It focused on measuring side effects, especially in the mouth and skin, to see if the combined treatment was tolerable. The trial was terminated early after enrolling only 3 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.